| Literature DB >> 31711420 |
Xue-Hua Li1, Zhuang-Nian Fang1, Tian-Ming Guan2, Jin-Jiang Lin1, Can-Hui Sun1, Si-Yun Huang1, Ren Mao3, Bao-Lan Lu1, Qing-Hua Cao1, Shi-Ting Feng4, Zi-Ping Li5.
Abstract
BACKGROUND: A validated histopathological tool to precisely evaluate bowel fibrosis in patients with Crohn's disease is lacking. We attempted to establish a new index to quantify the severity of bowel fibrosis in patients with Crohn's disease-associated fibrostenosis.Entities:
Keywords: Collagen fiber; Crohn’s disease; Fibrosis
Mesh:
Substances:
Year: 2019 PMID: 31711420 PMCID: PMC6849306 DOI: 10.1186/s12876-019-1100-3
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1The collagen area fraction for severe fibrostenosis was calculated as a histological fibrosis score of 4 in patients with colonic CD. a The fibrotic areas in the bowel wall that were stained using Masson trichrome are shown as a distinct blue region, and the blood, muscle, and inflammatory cells are shown in red. b The area of the bowel wall and (c) the area of collagen fiber within the bowel wall are automatically identified and divided by the area of the whole picture to the yield area ratio. The collagen area fraction = [30.22% / 64.07%] × 100% = 47.17%. CD, Crohn’s disease
Histologic score for fibrotic CD
| Score | Fibrosis |
|---|---|
| 0 | No fibrosis |
| 1 | Minimal fibrosis in submucosa or subserosa |
| 2 | Increased submucosal fibrosis, septa into muscularis propria |
| 3 | Septa through muscularis propria, increase in subserosal collagen |
| 4 | Significant transmural scar, marked subserosal collagen |
CD Crohn’s disease
Baseline Demographic and Clinical Characteristics of the Patients
| Gender: male / female | 12 /19 |
| Age, range, years | 18–63 |
| Disease duration, mean ± SD, months | 66.45 ± 63.77 |
| Smoking history | |
| Never | 21 (67.74%) |
| Current smoker | 4 (12.90%) |
| Former smoker | 6 (19.35%) |
| Therapy at the time of surgery | |
| Anti-TNF and immunosuppressant or corticosteroid | 11 (35.48%) |
| Anti-TNF | 14 (45.16%) |
| immunosuppressant | 6 (19.35%) |
| Surgery type, | |
| Ileocolon resection | 19/31 (61.29%) |
| Partial small bowel resection | 8/31 (25.81%) |
| Partial colon resection | 4/31 (12.90%) |
| Regions of disease involvement | |
| Ileum only | 5/31 (16.13%) |
| Ileum + jejunum | 3/31 (9.68%) |
| Ileum + jejunum+colon | 4/31 (12.90%) |
| Ileum + colon | 15/31 (48.39%) |
| Colon only | 4/31 (12.90%) |
| CDAI, mean ± SD | 232.12 ± 73.65 |
| CRP, mean ± SD, mg/L | 42.07 ± 21.19 |
| ESR, mean ± SD, mm/h | 41.37 ± 19.34 |
TNF Tumour necrosis factor; CDAI Crohn’s disease activity index, CRP C-reactive protein, ESR Erythrocyte sedimentation rate
Fig.2A scatterplot shows that there was strong correlation between the collagen area fraction and histological fibrosis score (r = − 0.733, P < 0.001)
Fig. 3On the ROC analysis, the collagen area fraction was slightly more accurate, with an AUC of 0.815 (95% CI = 0.721–0.910, P < 0.001), than the histological fibrosis score (AUC = 0.771; 95% CI = 0.666–0.877; P < 0.001) for diagnosing CD strictures. ROC, receiver operating characteristic; AUC, area under the ROC curve; CD, Crohn’s disease; CI, confidence interval
Fig.4A Bland–Altman analysis of the difference between the two observers for measuring the collagen area fraction. The Bland-Altman plot shows the LoA. The mean difference is shown as a solid line, the upper and lower 95% LoA are shown as black dashed lines, and the zero difference is shown as the blue dashed line. LoA, limits of agreement